Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-beta peptide (x->41) and tau
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 25, 2004
filing date -
Nov 14, 1994
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-.beta. peptide (x-.gtoreq.41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both A.beta.(x-.gtoreq.41) and tau. Low levels of A.beta.(x-.gtoreq.41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of A.beta.(x-.gtoreq.41) and low levels of tau are a negative indication of Alzheimer's disease.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully